SLC16A1 and Burkitt lymphoma: According to a preclinical study of Quanz and colleagues, the treatment of human Burkitt lymphoma tumor-bearing mice with novel and potent dual MCT1/MCT2 inhibitor BAY-8002, resulted in the intratumor accumulation of lactate [30].